Douglas C Beshore
Overview
Explore the profile of Douglas C Beshore including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
157
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Citron M, Zang X, Leithead A, Meng S, Rose Ii W, Murray E, et al.
J Infect
. 2024 Oct;
89(6):106325.
PMID: 39454831
Respiratory Syncytial Virus (RSV) causes severe respiratory infections and concomitant disease resulting in significant morbidity and mortality in infants, elderly, and immunocompromised adults. Vaccines, monoclonal antibodies, and small-molecule antivirals are...
2.
Tyagarajan S, Andrews C, Beshore D, Buevich A, Curran P, Dandliker P, et al.
ACS Med Chem Lett
. 2024 Oct;
15(10):1787-1794.
PMID: 39411537
The science of drug discovery involves multiparameter optimization of molecular structures through iterative design-make-test cycles. For medicinal chemistry library synthesis, traditional workflows involve the isolation of each individual compound, gravimetric...
3.
Skudlarek J, Cooke A, Mitchell H, Babaoglu K, Shaw A, Tong L, et al.
J Med Chem
. 2024 Aug;
67(17):15620-15675.
PMID: 39172133
, a commonly multidrug-resistant Gram-negative bacterium responsible for large numbers of bloodstream and lung infections worldwide, is increasingly difficult to treat and constitutes a growing threat to human health. Structurally...
4.
Kleiner V, Fischmann T, Howe J, Beshore D, Eddins M, Hou Y, et al.
Commun Biol
. 2023 Jun;
6(1):649.
PMID: 37337079
Respiratory syncytial virus (RSV) and human metapneumovirus (HMPV) are related RNA viruses responsible for severe respiratory infections and resulting disease in infants, elderly, and immunocompromised adults. Therapeutic small molecule inhibitors...
5.
Moore K, Schwaid A, Tudor M, Park S, Beshore D, Converso A, et al.
ACS Chem Biol
. 2022 Aug;
17(9):2595-2604.
PMID: 36044633
Although current antiretroviral therapy can control HIV-1 replication and prevent disease progression, it is not curative. Identifying mechanisms that can lead to eradication of persistent viral reservoirs in people living...
6.
Beshore D, Haidle A, Arasappan A, Lim Y, Raheem I, Roecker A, et al.
J Med Chem
. 2022 Feb;
65(5):3776-3785.
PMID: 35192762
Increasing the efficiency of the drug discovery process is a challenge faced by drug hunters everywhere. One strategy medicinal chemists employ to meet this challenge is learning from knowledge sources...
7.
Beshore D, Adam G, Barnard R, Burlein C, Gallicchio S, Holloway M, et al.
ACS Med Chem Lett
. 2021 Apr;
12(4):540-547.
PMID: 33854701
A novel series of histone deacetylase (HDAC) inhibitors lacking a zinc-binding moiety has been developed and described herein. HDAC isozyme profiling and kinetic studies indicate that these inhibitors display a...
8.
Salter R, Beshore D, Colletti S, Evans L, Gong Y, Helmy R, et al.
Xenobiotica
. 2018 Aug;
49(8):877-886.
PMID: 30118378
Metabolite identification is an integral part of both preclinical and clinical drug discovery and development. Synthesis of drug metabolites is often required to support definitive identification, preclinical safety studies and...
9.
Beshore D, Di Marco C, Chang R, Greshock T, Ma L, Wittmann M, et al.
ACS Med Chem Lett
. 2018 Jul;
9(7):652-656.
PMID: 30034595
Identification of ligands that selectively activate the M muscarinic signaling pathway has been sought for decades to treat a range of neurological and cognitive disorders. Herein, we describe the optimization...
10.
Preclinical to Human Translational Pharmacology of the Novel M Positive Allosteric Modulator MK-7622
Uslaner J, Kuduk S, Wittmann M, Lange H, Fox S, Min C, et al.
J Pharmacol Exp Ther
. 2018 Mar;
365(3):556-566.
PMID: 29563325
The current standard of care for treating Alzheimer's disease is acetylcholinesterase inhibitors, which nonselectively increase cholinergic signaling by indirectly enhancing activity of nicotinic and muscarinic receptors. These drugs improve cognitive...